Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, Maharashtra. The company is engaged in the manufacture and marketing of formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients, with operations spanning several countries across Asia, Europe, North America and Africa.
| Name | Wockhardt Limited |
|---|---|
| Industry | Pharmaceuticals, Biotechnology |
| Headquarters | Mumbai, Maharashtra, India |
| Country of origin | India |
| Areas of activity | Formulations, biopharmaceuticals, vaccines, active pharmaceutical ingredients |
| Listing | Bombay Stock Exchange, National Stock Exchange of India |
Wockhardt operates as an integrated pharmaceutical enterprise, combining research and development with large-scale manufacturing. The company has invested in biotechnology research, particularly in the development of recombinant biopharmaceuticals, and has expanded its presence internationally through acquisitions and the establishment of subsidiaries in markets including the United Kingdom, Ireland, France and the United States.
The group's structure includes its core pharmaceutical formulations business as well as a hospital chain, Wockhardt Hospitals, which operates tertiary-care facilities in several Indian cities. Over the years, the hospital business has been organised as a separate entity from the listed pharmaceutical company.
Wockhardt has established a manufacturing and marketing footprint outside India through a series of overseas acquisitions, giving it access to regulated markets in Europe and North America. Its international subsidiaries supply generic and specialty products to hospital and retail channels in those regions.
The company has been notable in India for its sustained investment in new chemical entity research aimed at antibiotic resistance. Several of its experimental antibacterial candidates have received qualified infectious disease product designations from the United States Food and Drug Administration, reflecting the priority given to such molecules under American antimicrobial development frameworks.
Wockhardt is considered one of the established Indian pharmaceutical companies with a presence in both small-molecule and biopharmaceutical manufacturing. Its work on novel antibiotics is among the relatively few new-drug discovery programmes pursued by an India-headquartered pharmaceutical firm, contributing to the country's profile in original pharmaceutical research alongside its better-known generics industry.